REvision of VSG with Ablation of the Mucosa Procedure
Dr. Christopher McGowan
Summary
The purpose of this study is to evaluate the feasibility, safety, and tolerability of endoscopic selective gastric mucosal ablation (GMA) using argon plasma coagulation after sleeve gastrectomy. In this study, GMA will be performed on patients who have experienced weight regain following an initial successful response to sleeve gastrectomy.
Description
Obesity is a multifaceted chronic disease associated with substantial morbidity and mortality, leading to conditions like diabetes, cardiovascular diseases, and malignancies. Bariatric procedures, such as the sleeve gastrectomy, stand out as the current most effective long-term treatments for obesity. Despite its effectiveness, a significant number of patients experience weight regain during long-term follow-up. Endoscopic minimally invasive bariatric intervention has been proposed as a viable, safe, and effective option for the treatment of weight regain after SG. Gastric mucosal ablation (GM…
Eligibility
- Age range
- 22–60 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Male and female patients who have: 1. BMI of 30 kg/m2 or greater, AND 2. regained at least 25% of the total weight lost after initial successful response to sleeve gastrectomy. defined as Excess Weight Loss (EWL) greater than 50% or Total Body Weight Loss (TBWL) exceeding 20% 2. Must have undergone SG at least three years before the time of enrollment 3. Age range: 22 - 60 years 4. Must agree to refrain from using weight loss medications such as Meridia, Saxenda, Januvia, Xenical, Duromine, GLP-1 agonists (e.g., Ozempic, Wegovy) and dual GLP-1/GIP agonists (e.g.,…
Interventions
- DeviceGastric Mucosal Ablation (GMA)
Endoscopic Gastric Mucosal Ablation (GMA) after sleeve gastrectomy
Location
- True You Weight LossCary, North Carolina